SCHEMBL1837286

SCHEMBL1837286

C[C@]1(O)C(O)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
MAPT P10636 1/20 0.43
POLB P06746 2/20 0.42
MAPK1 P28482 2/20 0.42
GAA P10253 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
NPC1 O15118 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
HIF1A Q16665 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SLC22A1 O15245 1/20 0.40
SYNJ2 O15056 3/20 0.39
HTT P42858 1/20 0.39
LGALS9 O00182 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1837289 1.00 ALDH1A1 (0.51) ALDH1A1MAPTPOLBMAPK1GAA
SCHEMBL3996036 0.89 HPGD (0.54) ALDH1A1MAPTGAAHPGDKMT2A
SCHEMBL3996032 0.89 HPGD (0.54) ALDH1A1MAPTGAAHPGDKMT2A
SCHEMBL13772424 0.89 HPGD (0.54) ALDH1A1MAPTGAAHPGDKMT2A
SCHEMBL5679345 0.88 UPP1 (0.47) ALDH1A1MAPTPOLBGAANPSR1
SCHEMBL13184474 0.88 ALDH1A1 (0.51) ALDH1A1MAPTPOLBMAPK1GAA
SCHEMBL13649108 0.88 ALDH1A1 (0.51) ALDH1A1MAPTPOLBMAPK1GAA
SCHEMBL13065704 0.88 ALDH1A1 (0.51) ALDH1A1MAPTPOLBMAPK1GAA
SCHEMBL21782410 0.88 ALDH1A1 (0.51) ALDH1A1MAPTPOLBMAPK1GAA
SCHEMBL5682469 0.88 ALDH1A1 (0.51) ALDH1A1MAPTPOLBMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631573-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO SpA (IT) 2006-03-08 EP claimed
US-6891036-B2 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2005-05-10 US claimed
WO-2004069851-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO S.P.A. (IT) 2004-08-19 WO claimed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 US claimed
EP-2319853-B1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS INC (US) 2014-03-12 EP disclosed
EP-2319853-A1 Process for the production of 2'-branched nucleosides Idenix (Cayman) Limited (KY) 2011-05-11 EP disclosed
US-7598373-B2 Process for the production of 2-C-methyl-D-ribonolactone IDENIX PHARMACEUTICALS, INC. (US) 2009-10-06 US disclosed
EP-1585529-A4 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX CAYMAN LTD (KY) 2008-05-28 EP disclosed
EP-1631573-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO SpA (IT) 2006-03-08 EP disclosed
EP-1585529-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES Idenix (Cayman) Limited (KY) 2005-10-19 EP disclosed
US-6891036-B2 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2005-05-10 US disclosed
US-20050020825-A1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS LLC 2005-01-27 US disclosed
WO-2004069851-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO S.P.A. (IT) 2004-08-19 WO disclosed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 US disclosed
WO-2004052899-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020825-A1 Process for the production of 2'-branched nucleosides RNGTT, MTAP, NSUN2 ALDH1A1 2027/4885MAPT 3665/4885POLB 68/4885
US-20040158059-A1 Process for the preparation of ribofuranose derivatives RNGTT, RPIA, MRM1 ALDH1A1 960/4885MAPT 4684/4885POLB 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.